ArticleCancers2022
Prevalence and Risk Factors for Hyposalivation and Xerostomia in Childhood Cancer Survivors Following Different Treatment Modalities-A Dutch Childhood Cancer Survivor Study Late Effects 2 Clinical Study (DCCSS LATER 2).
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Long-term oral and dental effects in childhood acute lymphoblastic leukemia survivors: a cross-sectional study comparing early and late post-treatment periods.BMC oral health · 2026Article
- Induction of oxidative stress and functional impairment by Doxorubicin in rat salivary glands.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Late Oral Complications in Childhood Cancer Survivors: Implications for Pediatric Dentistry and Survivorship Care.Children (Basel, Switzerland) · 2026Review
- Prevalence of late xerostomia and hyposalivation with associated risk factors in survivors of head and neck cancer after radiotherapy: a multi-centric cross-sectional study.Radiation oncology (London, England) · 2025Observational
- Drug-induced xerostomia and hyposalivation in patients with overactive bladder: a prospective open-label observational study comparing antimuscarinics and β3-adrenoceptor agonists.Scientific reports · 2025Observational
- Salivary gland macrophages in health and disease: heterogeneity, niche crosstalk, and therapeutic avenues.Frontiers in immunology · 2025Review
- Cancer treatment-related xerostomia: basics, therapeutics, and future perspectives.European journal of medical research · 2024Review
- A Narrative Review of the Association between Dental Abnormalities and Chemotherapy.Journal of clinical medicine · 2024Review
- Article
- Late Complications in Long-Term Childhood Cancer Survivors: What the Oral Health Professional Needs to Know.Dentistry journal · 2024Review
- The Approach to Dental Caries Prevention in a Case of Agenesis of the Major Salivary Glands: A Case Report.Cureus · 2024Article
- Review
- Oral Manifestations: A Warning-Sign in Children with Hematological Disease Acute Lymphocytic Leukemia.Hematology reports · 2023Review
- Self-reported outcomes on oral health and oral health-related quality of life in long-term childhood cancer survivors-A DCCSS-LATER 2 Study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 7 institutions in 2 countries.
Funding
Abstract
Background: Limited data are available on the risk factors of salivary gland dysfunction in long-term childhood cancer survivors (CCS). The objective of this cross-sectional study, part of the multidisciplinary multicenter Dutch CCS Study Late Effects 2 (DCCSS LATER 2), was to assess the prevalence of and risk factors for hyposalivation and xerostomia in CCS. Methods: From February 2016 until March 2020, 292 CCS were included. Data with regard to gender, age at study, diagnosis, age at diagnosis, and treatment characteristics were collected, as well as the unstimulated (UWS) and stimulated whole salivary flow rate (SWS). Xerostomia was assessed with the Xerostomia Inventory (XI) questionnaire. Multivariable Poisson regression analyses were used to evaluate the association between potential risk factors and the occurrence of hyposalivation. Results: The minimum time between diagnosis and study enrollment was 15 years. The prevalence of hyposalivation was 32% and the prevalence of xerostomia was 9.4%. Hyposalivation and xerostomia were not significantly correlated. Risk factors for hyposalivation were female gender and a higher dose of radiotherapy (>12 Gy) to the salivary gland region. Conclusion: Considering the importance of saliva for oral health, screening for hyposalivation in CCS is suggested in order to provide optimal oral supportive care aimed to improve oral health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.